Citigroup’s Transphorm, Inc. Common Stock TGAN Stock Holding History

Citigroup’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,945	Closed	-$24.3K	–	5837
2024 Q1	$24.3K	Buy	4,945 +773	+19%	+$3.67K	﹤0.01%	4971
2023 Q4	$15.2K	Buy	4,172 +4,159	+31,992%	+$11.4K	﹤0.01%	5077
2023 Q3	$29	Sell	13 -8,036	-100%	-$22.4K	﹤0.01%	5570
2023 Q2	$27.4K	Buy	+8,049	New	+$29K	﹤0.01%	4876
2023 Q1	–	Sell	-155	Closed	-$843	–	5956
2022 Q4	$843	Sell	155 -191	-55%	-$1.12K	﹤0.01%	5430
2022 Q3	$2K	Sell	346 -945	-73%	-$4.65K	﹤0.01%	5558
2022 Q2	$5K	Sell	1,291 -13,771	-91%	-$87.9K	﹤0.01%	5641
2022 Q1	$106K	Buy	+15,062	New	+$106K	﹤0.01%	4390

Citigroup's TGAN Position: Q2 2024 in Review

Citigroup sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 4,945 shares — an estimated $24.3K sold.

Citigroup first reported a position in TGAN in Q1 2022 and held it in 8 quarters. The position peaked at $106K in Q1 2022. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

Citigroup reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Citigroup sold 4,945 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $24.3K.
Citigroup first reported a position in Transphorm, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
Citigroup's Transphorm, Inc. Common Stock position peaked at $106K in Q1 2022.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on Citigroup's 13F filing for Q2 2024, filed 12 Aug 2024.